Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 52Prostatic Neoplasms 23Lung Neoplasms 17Breast Neoplasms 17Squamous Cell Carcinoma of Head and Neck 14Stomach Neoplasms 10Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 8Urinary Bladder Neoplasms 6Neoplasm Metastasis 6Head and Neck Neoplasms 6Carcinoma, Transitional Cell 6Triple Negative Breast Neoplasms 5Non-Muscle Invasive Bladder Neoplasms 5Carcinoma, Squamous Cell 5Prostatic Neoplasms, Castration-Resistant 4Ovarian Neoplasms 4Oropharyngeal Neoplasms 4Endometrial Neoplasms 4Small Cell Lung Carcinoma 3Salivary Gland Neoplasms 3Nasopharyngeal Carcinoma 3Laryngeal Neoplasms 3HER2-positive Breast Cancer 3Fallopian Tube Neoplasms 3Esophageal Squamous Cell Carcinoma 3Carcinoma 3Anatomic Stage I Breast Cancer AJCC v8 3Adenocarcinoma 3Vaccinia 2

Interventions

pembrolizumab 2Carboplatin 2tislelizumab 1cemiplimab 1aflutinib 1Pemetrexed 1Docetaxel 1Cisplatin 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Non-small Cell Lung Cancer × Docetaxel × 90 days × Clear all
NCT06868732 2026-03-30

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1 Recruiting
288 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡